Narcolepsy
RecruitingEfficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1
- Disease:Narcolepsy
- Substances:Alks 2680
Germany- Participants:18–64 years · 65+ years
- Substances:Alks 2680
- Sponsor:Alkermes Inc.
Rare diseases
Investigational molecules
Locations
Buerkle De La Camp-Platz 1, Wiemelhausen, 44789 Bochum, Germany
Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil gGmbH in Bochum, Germany specialises in clinical trials of conditions such as Narcolepsy, Obesity, Pain, Type 2 diabetes mellitus, and other specialisations. This site conducts important research.
At Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil gGmbH, clinical research in immune system diseases and nervous system diseases focuses on generalized myasthenia gravis and related neuromuscular weakness. These studies are designed to assess whether new treatments can better reduce symptoms and improve daily functioning for people living with this chronic condition.
Research at the site includes comparisons of emerging treatment options and efforts to improve care for patients who need better long-term disease control.
Clinical trials in skin and connective tissue diseases at the University Medical Center address deep partial and full-thickness burns. The main goal is to evaluate whether advanced skin repair approaches can support wound closure, limit scarring, and improve recovery after severe burn injury.
This area of research reflects a strong interest in restoring skin function and improving outcomes after complex trauma.
Trials in nutritional and metabolic diseases and hormonal diseases are examining overweight or obesity, type 2 diabetes, and polycystic ovary syndrome. The research aims to test whether new treatment strategies can improve metabolic control and help restore hormonal balance, especially in people affected by obesity-related reproductive problems.
These studies combine metabolic and reproductive health research to explore better ways to support patients with interconnected chronic conditions.
Research in cardiovascular diseases at this site includes studies in people with hypertension, cardiovascular disease, and diabetes-related heart risk. The trials are intended to determine whether new treatment combinations can reduce serious cardiac events and improve protection for patients with multiple cardiovascular risk factors.
This work highlights an emphasis on lowering the burden of heart disease in patients with complex metabolic and vascular conditions.
Clinical trials in nervous system diseases also include subacute moderate to severe traumatic brain injury. The purpose of this research is to examine whether new intranasal treatment approaches are safe, well tolerated, and potentially helpful in supporting recovery after brain injury.
This area adds to the site’s broader focus on neurological care and rehabilitation-related innovation.
Another key theme at Bergmannsheil is the study of generalized myasthenia gravis through direct comparisons of advanced immune-targeted therapies. The research is aimed at identifying which treatment may offer better symptom relief and overall benefit for patients beginning specialized care.
These investigations support more personalized treatment decisions in a difficult-to-manage autoimmune neuromuscular disease.
Clinical trials currently enrolling participants at this site.
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
GermanyGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.